FDA actions

April 2011
Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2
The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.


Related Articles

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • Escitalopram for Menopausal Hot Flashes.  // Travel Medicine Advisor;Mar2011 Supplement, p1 

    The article discusses various topics related to pharmacology. A study for escitalopram treatment of hot flashes in 205 menopausal women reveals the efficiency of the drug to reduce hot flashes severity. Meanwhile, a retrospective cohort study by Kaiser Permanente researchers in Southern...

  • Vaccine debate.  // Journal of Holistic Healthcare;Sep2008, Vol. 5 Issue 3, p4 

    The article reports on the debate concerning Zostavax, a vaccine for adult shingles, in the U.S. It states that the drug has been approved by the Food and Drug Administration (FDA) for use in adults age 60 and older. According to Dr. David Markovitz of FDA, the said drug has not been tested on...

  • Rite Aid Pharmacists Can Now Vaccinate Patients 50 and Older Against Shingles After FDA Lowers Age Eligibility.  // Biomedical Market Newsletter;4/30/2011, p117 

    The article reports that pharmacists of drugstore Ride Aid will able to administer shingles vaccine Zostavax to older patients aged 50 and above following the Food and Drug Administration's (FDA) expansion to the age eligibility for the shingles vaccine in the U.S. Robert Thompson, executive...

  • CancerVax Treatment Goes Skin Deep. Webb, Marion // San Diego Business Journal;5/19/2003, Vol. 24 Issue 20, p1 

    Assesses the efficacy of Canvaxin drug in treating patients with melanoma disease. Approval of the U.S. Food and Administration on the distribution of the vaccine in the market; Risks of side effects; Forms of skin cancer.

  • Vemurafenib Tablets (Zelborafâ„¢). Elliott, William T. // Internal Medicine Alert;10/29/2011, Vol. 33 Issue 20, p157 

    An abstract related to the U.S. Food and Drug Administration (FDA) review report conducted on the effectiveness of vemurafenib in patients with melanoma whose tumor expresses a gene mutation called BRAF V600E, is presented.

  • FDA approves Tafinlar, Mekinist for treatment of metastatic melanoma.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p26 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of dabrafenib and trametinib for treatment of melanoma patients.

  • Merck gets key approval on melanoma drug. Strauss, Eric // njbiz;9/15/2014, Vol. 27 Issue 37, p3 

    The article reports that the U.S. Food and Drug Administration has approved drug manufacturer Merck's Keytruda (pembrolizumab) drug as treatment for patients with certain types of advanced melanoma as of mid-September 2014.

  • REMS accompanies launch of new melanoma drug.  // Reactions Weekly;4/16/2011, Issue 1347, p4 

    The article reports on the approval of Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA) on March 26, 2011 for the treatment of unresectable or metastatic melanoma and the launching of a Risk Evaluation and Mitigation Strategy (REMS) by the drug's developer Bristol-Myers Squibb...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics